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ABSTRACT: We report the late-stage functionalization of multisubstituted
pyridines and diazines at the position α to nitrogen. By this process, a series of
functional groups and substituents bound to the ring through nitrogen, oxygen,
sulfur, or carbon are installed. This functionalization is accomplished by a
combination of fluorination and nucleophilic aromatic substitution of the installed
fluoride. A diverse array of functionalities can be installed because of the mild
reaction conditions revealed for nucleophilic aromatic substitutions (SNAr) of the 2-fluoroheteroarenes. An evaluation of the
rates for substitution versus the rates for competitive processes provides a framework for planning this functionalization
sequence. This process is illustrated by the modification of a series of medicinally important compounds, as well as the increase in
efficiency of synthesis of several existing pharmaceuticals.
■ INTRODUCTION
Pyridines and diazines are among the most prevalent
heterocycles in biologically active compounds. They are
found in 2 of the 5 top-selling pharmaceuticals1 and 6 of the
23 small molecules approved by the FDA in 2013.2 Of course,
the groups appended to the heteroarene and the heteroarene
core together affect the activity of the molecule, not just the
heteroarene itself. Thus, studies of the structure−activity
relationships (SAR) require derivatives containing a range of
substituents attached to pyridines and diazines. One potential
method to create these derivatives is C−H bond functionaliza-
tion of the heteroarene. Yet, few C−H bond functionalization
reactions are amenable to late-stage functionalization of
heteroarenes. Instead, multistep syntheses are typically
conducted to study the effects of substituents on the
heteroarene units.
Some C−H bond functionalization reactions of heteroarenes
have been developed that exploit a directing group, but
methods for site-selective functionalization without the
influence of such groups would allow modifications at different
positions and without the need to install and remove such
groups.
Three major classes of reactions lead to the functionalization
of C−H bonds in pyridines and diazines without the influence
of directing groups. The first class comprises Minisci-type
reactions, which occur by the addition of carbon-centered
radicals to heteroarenes (Scheme 1A).3,4 These reactions are
versatile, but mixtures of isomers are formed in most cases, and
the regioselectivity depends on the steric and electronic
properties of both the heteroarene and the radical partner.3a,5
A second class of heteroarene C−H bond functionalization
reactions includes additions of nucleophiles to pyridine N-
oxides in combination with a reagent to activate and dehydrate
the pyridine N-oxide (Scheme 1B). Reactions of this type have
been developed to install Br, Cl, CN, amino, phenoxy, and
nucleophiles derived from reagents containing acidic C−H and
N−H bonds (pKa range of ∼10−20).
6 In most cases, the scope
of the pyridine N-oxides that undergo these reactions is limited
to those containing ether, ester, and nitrile substituents or
halides at positions not reactive toward SNAr. In general,
functionalization occurs at the 2-position, but competing
functionalization at the 4-position or on pendant alkyl groups
is often observed. In addition to these issues of functional
group compatibility and site selectivity, the need to prepare and
isolate the N-oxides limits the use of these reactions.
Most closely related to the work reported here, C−H
functionalization reactions at the 2-position of pyridines and
pyridine N-oxides have been developed with transition metal
catalysts.7 However, these reactions are limited to the formation
of C−C bonds, and the reaction conditions and scope suggest
that these reactions are not suitable for complex substrates.8
Other functionalizations of heteroaryl C−H bonds involve
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Scheme 1. Strategies for C−H Functionalization of Pyridines
Article
pubs.acs.org/JACS
© 2014 American Chemical Society 10139 dx.doi.org/10.1021/ja5049303 | J. Am. Chem. Soc. 2014, 136, 10139−10147
Terms of Use
cross-coupling at the most acidic C−H bond; these methods
occur most commonly with five-membered ring heteroarene-
s.7a−c
Finally, C−H borylation reactions catalyzed by transition
metal complexes provide a means to install substituents onto
heteroarenes by conversion of the heteroarene to the
corresponding heteroarylboronate ester and subsequent trans-
formations of the C−B bond.9 However, borylations of
pyridines occur predominantly at the 3- and 4-positions and,
therefore, are complementary to the reactions at the 2-position
described here.
We aimed to develop a method for the late-stage
functionalization of pyridines and diazines that would address
the limitations of the regioselectivity and scope of C−H
functionalizations of heteroarenes. Our approach was inspired
by the value of borylation reactions developed in the authors’
laboratory to create synthetic intermediates that can be
converted to a variety of functionalized products.9b We
considered that the C−H fluorination of pyridines and
diazines10 at the position α to nitrogen with AgF2 we
developed recently could be used for the late-stage function-
alization of medicinally relevant compounds because pyridines
and diazines are contained in many such compounds and the 2-
fluoro group could be replaced with a wide range of
nucleophiles.
Herein, we report mild conditions for the SNAr reaction of
fluoroheteroarenes, an assessment of the potential of the
fluorination and SNAr reactions to be conducted with complex
structures, and the application of these findings to the
development of late-stage functionalizations of complex
heterocyclic compounds by the combination of C−H
fluorination and SNAr reactions (Scheme 1C). In addition to
revealing the potential of this reaction for the functionalization
of complex heteroarenes, we demonstrate how the combination
of C−H bond fluorination and SNAr creates routes to several
active pharmaceutical ingredients that occur in higher yields
and fewer steps than previously reported syntheses of these
molecules.
■ RESULTS AND DISCUSSION
Conditions for the Nucleophilic Aromatic Substitu-
tion of 2-Fluoropyridines. SNAr reactions of 2- or 4-
halopyridines comprise a site-specific method to synthesize
substituted pyridines.11 However, this approach requires initial
synthesis and isolation of halogenated pyridines that are
typically prepared from pyridine N-oxides or hydroxypyridines
with neat POX3 (X = Br, Cl) at high temperatures.
The majority of SNAr reactions with halopyridines have been
performed with chloropyridines. Chloropyridines are more
available commercially than other halopyridines, but the
reactions of fluoropyridines are likely to be faster than those
of chloropyridines. As for SNAr reactions of arenes, the SNAr
reactions of pyridines and diazines are likely to be accelerated
by the high electronegativity of fluorine. Indeed, the reaction of
2-fluoropyridine with NaOEt in EtOH is 320 times faster than
the reaction of 2-chloropyridine.12 This higher reactivity of
fluoropyridines could allow SNAr reactions to occur under
conditions that are mild enough to allow this class of reaction
to occur on complex molecules; however, a more detailed
assessment of the rates and yields for the SNAr reactions of
fluoropyridines and diazines would be needed to predict the
scope of the SNAr process and a method to create the 2-
fluoropyridines and diazines that could be conducted in a
typical laboratory on complex pyridines and diazines would be
required.
Thus, to develop a sequence of C−H bond fluorination and
SNAr, we first evaluated conditions to conduct SNAr reactions
of 2-fluoropyridines. Although SNAr reactions of electron-
deficient fluoroarenes and chloropyridines are commonplace,11
few studies have been performed on SNAr reactions of
fluoropyridines.13 The majority of the published reactions of
2-fluoropyridines have been conducted with unsubstituted 2-
fluoropyridine; a few examples were conducted with 2-
fluoropyridines containing a single bromide substituent.
Moreover, these reactions were performed under conditions
involving strong nucleophiles and bases at high temperatures
(up to 130 °C), neat reagents, microwave heating, strong
reducing agents (LiBH3NR2), or toxic solvents (HMPA), and
these conditions are unlikely to tolerate the functional groups
found in complex molecules relevant to medicinal chemistry.
Several SNAr reactions of 2-fluoropyridines have been reported
in the patent literature on both simple and complex substrates.
However, the reactions described in these documents for a
given class of nucleophile occur under varying conditions.
Therefore, the scope of each set of reaction conditions is
unclear, and the SNAr reactions were performed with activated
2-fluoropyridines in most cases. From this body of work, it was
unclear whether mild and general SNAr reactions with
fluoroheteroarenes could be developed and if selectivity could
be obtained for substitution of fluoride over other halides. In
fact, previous reports showed that the same forcing reaction
conditions lead to substitution of F, Cl, Br, and I.
To identify conditions for the SNAr reaction that would
tolerate common functionality, we studied reactions of
unactivated 2-fluoropyridines with nucleophiles derived from
alcohols, phenols, amines, amides, N-heterocycles, cyanide, and
thiols under relatively mild conditions. The reaction conditions
we identified afforded quantitative conversion to the sub-
stitution products, as indicated by GC/MS and TLC (Table 1).
Reactions with KCN proceeded in approximately 80% yield.
Variation of the cyanide source, stoichiometry, temperature,
and solvent did not increase the yield, but the initial conditions
did form the cyanopyridine product in a synthetically useful
yield. Having developed a set of SNAr reactions that occur
under mild conditions, we explored the tandem fluorination−
substitution process.
For the SNAr reactions to occur in tandem with C−H
fluorination, the MeCN and silver salts from the fluorination
reaction needed to be removed. Filtering the fluorination
Table 1. Reaction Conditions for the SNAr of 2-
Fluoropyridines
NuH base solvent
temp
(°C)
time
(h)
conv
(%)
1, 2, or 3° alcohol KOtBu THF 50 3 100
ArOH KOtBu DMF 80 6 100
1 or 2° amine iPr2NEt DMSO 120 18 100
amide (N−H) NaH DMF 100 3 100
N-heterocycle NaH DMF 100 1−3 100
KCN (3 equiv) DMSO 120 18 ∼80
NaSR THF 50 3 100
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reactions through a short silica-filled pipet and evaporating the
solvent was sufficient to perform the subsequent SNAr
reactions. Yields of the SNAr reactions conducted after filtering
the fluorination reaction through Celite were low, due to the
presence of soluble Ag salts.
Convenient Protocols for Performing the Fluorination
of Pyridines and Diazines. For the fluorination−SNAr
sequence to be used broadly, procedures for conducting the
reaction without specialized equipment for excluding air and
moisture are needed. AgF2 is a hygroscopic solid that
decomposes in the presence of water. Therefore, during our
initial study, the fluorination reactions were assembled in a
glovebox with rigorously dried MeCN.10 However, despite the
water sensitivity of AgF2, simple procedures can be followed for
conducting the reactions without rigorous exclusion of air or
moisture.
To assess the impact of water and oxygen on the yield of the
fluorination reaction of complex molecules, we performed a
series of experiments with (CO2Me)-vismodegib, a drug
recently approved for the treatment of basal-cell carcinoma
(Table 2). Assembling the fluorination reaction in a glovebox
(oxygen and water content <1 ppm), in an oven-dried vial, with
MeCN that had been rigorously dried over CaH2, afforded the
fluorinated vismodegib derivative in 99% yield by 19F NMR
spectroscopy.
Since the use of a glovebox is not practical for all chemists,
we studied the effects of weighing the solid reagents in air and
assembling the reaction using standard air-free techniques. A
reaction was assembled by adding the pyridine substrate to a
dry vial in air and adding MeCN that had been dried over
CaH2. AgF2 was weighed quickly in air, added to the pyridine
solution, and the vial was sealed under an atmosphere of N2.
The reaction assembled in this manner afforded the 2-
fluoropyridine product in 84% yield, only a slight decrease in
yield compared to the reaction assembled entirely in the
glovebox. Performing the reaction in a similar manner with a
nondried vial and sealing the reaction under an atmosphere of
air (2 mL of MeCN in a 4 mL vial; 2 mL headspace of air)
resulted in a similar yield of the fluoropyridine product (79%).
Acetonitrile dried with 5 wt % of 3 Å molecular sieves for 24
h was a suitable solvent; the reaction of (CO2Me)-vismodegib
with AgF2 assembled by weighing the solid reagents in air in a
nondried vial sealed under an atmosphere of air afforded the
fluorinated product in 85% yield. The water content in MeCN
dried over 5 wt % molecular sieves for 24 h is near 4 ppm, and
the water content further decreases with time.14 The water
content of commercial “anhydrous” MeCN is below 10 ppm
water and should be equally suitable for this reaction.
Finally, the same reaction was assembled in air with ACS
grade MeCN directly from a commercial bottle that had been
opened and used over the course of a year; a noticeable
decrease in yield to 65% was observed, but a substantial amount
of product was still formed. Together, these results demonstrate
that these fluorination reactions can be conveniently assembled
completely in air, without the use of a glovebox or air-free
techniques, and with MeCN dried over molecular sieves, even
though AgF2 is sensitive to water and should be stored under an
inert atmosphere. Reactions performed on the benchtop occur
in yields that are comparable to those performed under
rigorously anhydrous reaction conditions.
AgF2 is supplied as a black, microcrystalline solid, which
should be stored under an inert atmosphere. Because AgF2
undergoes decomposition with moisture, a noticeable color
change from black to yellow or brown is observed when it is
stored in air. For all reactions reported here, and in our
previous paper,10 AgF2 was used as received from Alfa Aesar
and stored under a nitrogen atmosphere in a plastic bottle. In
our experience, reactions with AgF2 supplied from Strem
occurred in comparable rates and yields to those performed
with AgF2 puchased from Alfa Aesar.
Scope of the Tandem C−H Fluorination and Nucleo-
philic Aromatic Substitution of Pyridines. Having
identified convenient methods for conducting both the
fluorination and SNAr reactions and having developed a
protocol to conduct the two reactions in sequence, we
investigated the scope of the C−H bond fluorination−SNAr
process. Representative examples illustrating the scope of the
combined reactions are shown in Tables 3 and 4. Yields given
are for isolated products starting from the heteroarene. The
yields for the fluorination step are also shown to illustrate how
the values for the two-step process compare to those of the first
step.
A variety of pyridines that are sterically hindered (2, 4, 11,
12, 14, 15) and/or electronically deactivated (2, 9, 13, 15)
toward SNAr reactions afforded the substitution products in
good yields. Substrates containing alkyl groups in the 2-position
reacted selectively at the 6-position (2, 4, 9, 14), while
analogous reactions with pyridine N-oxides are known to result
in substitution of a C−H bond on the alkyl group (Scheme
1B). A wide range of functional groups were tolerated,
including ethers, halides, ketones, acetals, esters, amides, ethyl
and t-butyl carbamates, nitriles, and sulfones. It is notable that
the azetidine in 11 (Table 4) did not undergo ring opening, a
competing reaction observed under acidic conditions.15
The reactions of chloropyridines 7 and 11 revealed a high
selectivity for substitution of a fluoride over a chloride under
conditions of the SNAr reactions shown in Table 1. This high
selectivity, along with the high functional group compatibility, is
attributed to the milder reaction conditions we developed for
the SNAr reaction at the 2-fluoro position, relative to the
conditions typically used to conduct substitutions with 2-
fluoropyridines. In sum, this work shows that fluoropyridines
undergo substitution reactions under conditions much milder
than previously reported and can be performed in the presence
of a wide range of functional groups, including those that are
electrophilic.
Table 2. Assessing the Impact of Water and Air on the
Fluorination Reaction with AgF2
a
method of drying
MeCN
rxn vial
dried
solids
weighed atmosphere
yield (%)
(NMR)
CaH2 yes in glovebox N2 99
CaH2 yes in air N2 84
CaH2 no in air air 79
molecular sieves no in air air 85
none no in air air 65
aReactions were performed with 0.2 mmol of (CO2Me)-vismodegib
with 2 mL of MeCN in 4 mL vials.
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Tandem C−H Fluorination and Nucleophilic Aromatic
Substitution of Diazines. Six-membered heteroarenes
containing two nitrogen atoms (diazines) are prevalent
subunits in medicinal chemistry. Radical addition reactions to
diazines are commonplace3 (Scheme 1A), but a single example
of C−H bond functionalization by nucleophilic addition of a
heteroatom to a diazine N-oxide (Scheme 1B) has been
demonstrated.6c Like pyridines, diazines react with AgF2 with
exclusive selectivity for fluorination adjacent to nitrogen.10
Thus, we considered that the combination of C−H bond
fluorination and SNAr reactions could be conducted with these
heterocycles to form functionalized diazine products.
Indeed, pyrimidines (5, 6) and pyrazines (8) reacted in the
two-step sequence following the standard conditions we
developed for the fluorination and SNAr reactions reported in
Table 1. This sequence allowed several polysubstituted diazines
to be prepared through C−H functionalization. Because the
conditions for both the fluorination and the SNAr reactions with
diazines are the same as those for pyridines, the tolerance of the
reactions toward functional groups on pyridines and diazines
should be comparable. This C−H fluorination−SNAr sequence
was also applied to the synthesis of a reverse transcriptase
inhibitor containing a tetra-substituted pyrimidine (vide infra).
Late-Stage Functionalization of Complex Molecules
via Tandem C−H Fluorination and Nucleophilic Ar-
omatic Substitution. With conditions established for the
fluorination and SNAr reactions of pyridines and diazines, we
evaluated this sequence for the late-stage functionalization of
more complex molecules in medicinal chemistry. First, we used
our tandem sequence to prepare several 2-substituted
derivatives of (Boc-protected) betahistine (9), a histamine
agonist used in the treatment of Meńier̀e’s disease. Reaction of
9 with AgF2 formed the corresponding 2-fluoropyridine in
nearly quantitative yield (98%). This electronically deactivated
fluoropyridine intermediate reacted with nucleophiles derived
from butanol, morpholine, and indole to provide several 2-
substituted analogues of betahistine. Although betahistine is a
relatively simple compound that can be prepared in one step
from 2-vinylpyridine, the synthesis of derivatives that are similar
to those we report here would require 2-substituted 6-
vinylpyridines. Few such pyridines are commercially available.16
Thus, our C−H bond fluorination−SNAr strategy for late-stage
functionalization avoids lengthy synthetic sequences to prepare
derivatives of betahistine.
We also conducted the fluorination of compound 10, the
direct precursor to loratadine (Claritin) and desloratadine
(Clarinex), two common antihistamines. Compound 10 is
prepared in two steps from 3-methylpicolinic acid under
relatively harsh reaction conditions (nBuLi, KOtBu for the first
step; SOCl2, AlCl3 for the second step).
17 Therefore, the
synthesis of 2-substituted derivatives of 10 would require access
to the appropriately substituted 3-methylpicolinic acid, which
could require several steps to prepare, and an additional two-
step sequence to construct the tricycle for each derivative. We
prepared various analogues of 10 more directly through
fluorination and SNAr reactions to form the corresponding 2-
alkoxy-, 2-amino-, and 2-pyrazolyl-substituted derivatives. It is
worthy to note that the substituents we installed in 10a−10c
would be unlikely to tolerate the conditions of a de novo
synthesis of similar analogues of 10.
Table 3. Tandem C−H Fluorination and SNAr
a
aIsolated yields from the two-step sequence for reactions performed
with 0.2 mmol of heteroarene. Yields in parentheses were determined
by 19F NMR spectroscopy for the independent fluorination reaction.
bThe isolated product contained ∼5% of an inseparable impurity. cThe
Boc group was cleaved during the SNAr reaction.
Table 4. Tandem C−H Fluorination and SNAr of Medicinally
Important Compoundsa
aIsolated yields from the two-step sequence for reactions performed
with 0.2 mmol of heteroarene. Yields in parentheses were determined
by 19F NMR spectroscopy for the independent fluorination reaction.
bThe isolated product contained ∼5% of an inseparable impurity.
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Our C−H functionalization method also gave access to a
series of (Boc-protected) derivatives of tebanicline (11), a
potent non-opiod analgesic that is structurally related to several
nicotinic acetylcholine receptor agonists. As mentioned above,
no ring opening of the azetidine or substitution of the chloride
was observed. De novo syntheses of compounds similar to
11a−11c would require access to 2-substituted 3-hydroxy-6-
chloropyridine substrates and an additional C−O bond-forming
reaction to complete the synthesis of each derivative.
The sequence of C−H bond fluorination and SNAr also led
to a convenient synthesis of 2-alkoxy and 2-amino analogues of
roflumilast (12). Roflumilast is a recently approved PDE-4
inhibitor used in the treatment of chronic obstructive
pulmonary disease. The reported syntheses of this compound
involve amide bond formation with 3,5-dichloro-4-amino-
pyridine. Thus, the syntheses of the 2-substituted analogues
we report would require access to 2-alkoxy or 2-amino-3,5-
dichloro-4-aminopyridine, for which none are commercially
available. Therefore, preparing derivatives of roflumilast would
mandate multistep syntheses of the appropriate pyridine, in
addition to performing the subsequent amide bond formation
for each derivative. In contrast, the C−H fluorination−SNAr
strategy we report allows rapid access to analogues that would
otherwise require several synthetic steps to prepare.
In a similar manner, analogues of the precursor to
pirenzepine (13), a benzodiazepine-based M1-selective antag-
onist used for the treatment of ulcers, were prepared. The
sequence was used to install alkoxy, thio, and aryloxy
substituents at the 2-position in good overall yields. Competing
reactions at the electrophilic ethyl carbamate were not
observed. The synthesis of the core of 13 requires three steps
from 2-chloro-3-aminopyridine.
Relative Rates for the Fluorination of Pyridines and
Diazines Having Different Electronic Properties. Because
many medicinally important compounds contain multiple
heteroaryl rings, it would be valuable if the fluorination was
selective for the functionalization of one type of ring system
over another. The proposed mechanism10 for the fluorination
of pyridines and diazines with AgF2 (eq 1) is initiated by
coordination of the basic nitrogen to silver. This coordination
could cause a more basic heterocycle to be more reactive than a
less basic heterocycle. However, the second step in the
proposed mechanism is addition of fluoride to the π system,
which would be favored for a more electron-deficient
heteroarene. Finally, the third step, a formal oxidation of the
heterocycle through hydrogen atom abstraction, would likely be
favored for a more electron-rich substrate. Our previous studies
of the selectivity between pyridine and pyridine-d5 demon-
strated that coordination of AgF2 to pyridine is reversible and
that cleavage of the C−H bond is irreversible.10
To determine how the electronic properties of the
heteroarene influence the relative rates of fluorination, we
conducted a series of competition experiments. In these
experiments, AgF2 was allowed to react with a 1:1 mixture of
two different pyridines and diazines. Because the yield of the
fluorination reactions conducted with a large excess of pyridine,
relative to AgF2, is low, reactions containing 1 equiv of each
heteroarene (0.1 mmol each) and 2 equiv of AgF2 (0.2 mmol)
were run, and the reactions were quenched after 15 min so that
the selectivities were being measured at low conversion (25 ±
2%). Competition experiments between 2-ethyl, 2-methoxy,
and 2-chloropyridine were conducted; the steric properties of
these substrates are similar to each other, but the basicity of the
heterocycles differ incrementally from each other by ∼2.6 pKa
units. Competition experiments were also conducted between
alkyl-substituted pyridines, pyrimidines, and pyrazines contain-
ing two available C−H bonds for fluorination. The results of
these competition experiments are shown in Table 5. These
data show that more Lewis basic pyridines undergo the C−H
fluorination reactions in preference to less Lewis basic
pyridines. Moreover, exclusive selectivity for fluorination of a
4-alkylpyridine over two alkyl-substituted diazines was
observed; the competition between 2-methylpyrimidine and
2,3-dimethylpyrazine showed that the pyrimidine was the more
reactive diazine by a factor of 3.3.
The results of these competition experiments contrast with
what would be predicted based only on the relative rates of
independent reactions between each substrate and AgF2. 2-
Ethylpyridine reacts with 2 equiv of AgF2 to give 38% yield of
the 6-fluoropyridine after 15 min. Similarly, 2-methoxypyridine
reacts in 36% yield, and 2-chloropyridine reacts in 9% yield
after 15 min. Because the rates for fluorination of 2-
ethylpyridine and 2-methoxypyridine are comparable, and
because AgF2 is present in excess, little selectivity for 2-
ethylpyridine over 2-methoxypyridine would be expected based
on these data alone. However, AgF2 has negligible solubility in
MeCN; therefore, competitive binding of the two substrates to
the limited amount of available AgF2 likely results in
fluorination of the more basic pyridine.
Table 5. Competition Experiments between Electronically
Different Pyridines and Diazines with AgF2
a
aProduct ratios were determined by 19F NMR spectroscopy of the
crude reaction mixture after quenching with aqueous NaHCO3.
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To assess the relative reactivity of multiple pyridines in the
context of a medicinally important compound, we conducted
the fluorination and SNAr reaction of etoricoxib (eq 2), a
selective COX-2 inhibitor used in the treatment of arthritis.
This compound contains two different pyridine rings. The
more electron-rich ring contains methyl and 2-pyridyl
substituents, and the less electron-rich ring contains chloro,
aryl, and 3-pyridyl substituents. This molecule reacted with
AgF2 with complete selectivity for fluorination of the more basic
pyridine system, as predicted from the results in Table 5. No
product resulting from fluorination of the 3-chloropyridine was
observed. Following this site-selective fluorination, several
derivatives of etoricoxib containing pendant alkoxy, amino,
cyano, and pyrazolyl units were prepared.
Site Selectivity for the Fluorination of 3,5-Disubsti-
tuted Pyridines. Many medicinally active pyridines contain
two inequivalent C−H bonds that could undergo fluorination
with AgF2. We previously demonstrated
10 that several 3-
substituted pyridines undergo fluorination with exclusive
selectivity to form the 2-fluoro-3-substituted pyridine product.
The 3-substituted pyridines that react selectively at the 2-
position include those containing 3-halo, alkoxy, cyano, or CF3
groups. 3-Substituted pyridines that give a mixture of 2-
fluoropyridine isomers include those containing 3-alkyl, 3-
CO2R, and 3-C(O)NR2 substituents. It was unclear from these
results if 3,5-disubstituted pyridines would undergo the
fluorination selectively. A set of 3,5-disubstituted pyridines
containing phenyl, cyano, benzyloxy, bromo, methyl, and CF3
substituents was prepared. The fluorination of the 15
unsymmetrical pyridines containing these substituents occurred
with poor site selectivity (from 1:1 up to 6:1), with the
exception of the benzyloxy-substituted pyridines. The 3-
benzyloxy-substituted pyridines containing various substituents
in the 5-position reacted with AgF2 with modest to high
selectivity (4.2:1 to 20:1) for fluorination adjacent to the ether
substituent (Table 6).
Having shown that an alkoxy group can lead to selective
fluorination of a 3,5-disubstituted pyridine, we exploited this
selectivity to conduct the late-stage fluorination of a medicinally
relevant, 3,5-disubstituted pyridine. The core of crizotinib (eq
3), a drug used for the treatment of metastatic non-small cell
lung cancer, contains such a heteroaromatic unit. Reaction of
15 with AgF2 gave products reflecting a 7.2:1 selectivity for
fluorination adjacent to oxygen. This selectivity is lower than
that observed for the fluorination of 3-bromo-5-benzyloxy-
pyridine (Table 6), likely due to the steric hindrance of the
arylethoxy substituent. To determine if the lower selectivity of
this substrate is due to the greater steric hindrance of the
benzyloxy group of 15 than that of a simple benzyloxy
substrate, the fluorination reaction was also performed with a
2,6-dimethylphenyl arylethoxy substrate. This compound
reacted in 62% yield with similar 5.9:1 selectivity for
fluorination adjacent to the ether substituent. Thus, the
selectivity is lower for reactions of pyridines containing more
hindered benzyloxy groups but is still significant. The steric
hindrance of the arylethoxy substrates disfavors both the
second and third steps in our proposed mechanism (eq 1)
leading to an increase in the relative amount of product from
fluorination adjacent to the bromide.
Even though the 2-fluoro-3-benzyloxypydridine intermediate
is both sterically and electronically deactivated toward SNAr,
several 2-substituted derivatives were prepared under the
standard conditions for the SNAr step shown in Table 1.
Even a secondary amine reacted with the 2-fluoropyridine to
form the sterically congested product 15c. The isomeric
products prepared from 15 after C−H bond fluorination−SNAr
reactions were not separable by standard silica gel chromatog-
raphy, even though the 2-fluoropyridine isomers could be
separated by HPLC and GC.
Limitations of the C−H Fluorination and SNAr
Reactions. Although we have demonstrated that the C−H
fluorination and SNAr reactions occur with broad scope and can
be conducted on complex molecules, there are some
limitations. As we reported previously,10 the fluorination
reaction is not compatible with free amines or alcohols,
carboxylic acids, aldehydes, or electron-rich five-membered
heterocycles; however, several protected derivatives of these
groups are tolerated by AgF2. In addition, we have found that
pyridines or diazines containing multiple electron-withdrawing
substituents undergo the fluorination reaction in lower yields
than those containing electron-neutral or electron-donating
groups. Examples of substrates that reacted with AgF2 in low
yields (0−30%) are shown in Table 7. Although the Boc-
protected derivative of HG-10-102-01 reacted with AgF2 in low
yield, a similar tetra-substituted pyrimidine reacted in high yield
for the synthesis of etravirine (vide infra).
We have demonstrated that a simple set of SNAr reaction
conditions can be employed for substitution reactions on a
variety of 2-fluoroheteroarenes. However, we did find substrates
Table 6. Fluorination of 3,5-Disubstituted Pyridines
X temp (°C)
concentration
(M)
ratio
(D/E)
combined yield (%)
(D+E)
Br 50 0.050 15:1 49
CI 50 0.025 8.1:1 64
Me 50 0.025 >20:1 62
Ph 50 0.050 4.2:1 68
CN 50 0.025 12:1 67
CF3 rt 0.050 20:1 85
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that underwent competing side reactions faster than they
underwent SNAr (Table 7). Fluorinated analogues of
tropicamide underwent retro-Michael addition under the
basic reaction conditions. Although we demonstrated that
tert-butyl esters remain intact during the SNAr reactions (Table
3, substrate 3), we found that aryl acetates are cleaved faster
than substitution of fluoride. This cleavage was observed when
attempting SNAr reactions of bisacodyl. Finally, very electron-
rich and sterically hindered pyridines, such as the precursor to
Nexium, underwent the SNAr step in low yields; more forcing
conditions resulted in the formation of side products.
Applications of C−H Fluorination and SNAr for the
Synthesis of Medicinal Compounds. Having demonstrated
the potential of the C−H fluorination−SNAr sequence for the
late-stage derivatization of medicinally important compounds,
we sought to evaluate whether the same strategy could create
shorter and higher-yielding synthetic routes to the same types
of compounds. Although this chemistry requires stoichiometric
silver and is not designed for process-scale chemistry, the
strategy of C−H fluorination and SNAr can be useful in
discovery chemistry. One example of a synthesis that could be
simplified by the fluorination and substitution process is the
synthesis of the simple compound 6-(methylamino)-2-pyridine-
ethanol (Scheme 2, 16). Compound 16 is a precursor to several
important compounds, including the integrin inhibitor SB-
273005 (Scheme 2C). Although 16 is structurally simple, the
two reported syntheses of 16 by medicinal chemists were
conducted in five and seven steps from 2-amino-6-methyl-
pyridine (Scheme 2A). We considered that the 2-methylamino
group could be installed through C−H bond fluorination and
SNAr from a derivative of 2-pyridineethanol.
Fluorination did not occur on the free alcohol, but it did
occur after protecting the alcohol as an ester. An acetyl
protecting group was chosen because it could be cleaved in
concert with the SNAr reaction. The fluorination of acetylated
2-pyridineethanol occurred in 88% yield (by 19F NMR
spectroscopy). Treatment of the crude mixture from the
fluorination step with aqueous MeNH2 in DMSO led to
formation of the methylaminopyridine unit and cleaveage of the
acetyl group to reveal the free alcohol. This route gave 16 with
only two isolations in 64% overall yield, a significantly shorter
and higher-yielding approach than the reported syntheses
requiring five or seven steps. Although our route requires
stoichiometric silver, it is worthy to note that an improved
process used to prepare 30 g of 16 still required four steps and
occurred in only 39% overall yield.18
The combination of C−H bond fluorination and SNAr also
shortened the synthesis of PF-1247324, a potent and selective
NaV1.8 inhibitor (Scheme 3).
19 The medicinal chemistry route
to this compound comprised six steps and occurred in less than
1% yield; an advanced intermediate was outsourced for the
kilogram-scale synthesis of PF-1247324.20 Our route to this
compound began with the fluorination of methyl 5-bromo-
Table 7. Substrates that Reacted in Low Yields for the C−H
Fluorination or SNAr Reactions
Scheme 2. Synthesis of 6-(Methylamino)-2-pyridineethanol
through C−H Fluorination
Scheme 3. Synthesis of PF-1247324 through C−H
Fluorination
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picolinate. The fluoropyridine intermediate contains two
electrophilic sites for nucleophilic substitution: a methyl ester
and a 2-fluoropyridine. We demonstrated (Tables 3 and 4) that
substitution at the fluorine of a 2-fluoropyridine can occur in
the presence of auxiliary electrophilic functional groups,
including a tert-butyl ester. However, we considered that
conditions could be identified to transform the methyl ester to
the N-methyl amide without substitution of the fluoride. The
reaction between the fluoropyridine methyl ester with aqueous
MeNH2 in THF formed a mixture of products resulting from
substitution of both methoxide and fluoride. However, simply
changing the reaction solvent from THF to MeOH allowed for
the selective transformation of the methyl ester to the N-methyl
amide without substitution of the f luoride.
After aqueous workup, the crude reaction mixture was
treated with ammonium hydroxide in DMSO to substitute an
NH2 group for the fluoride. Finally, the 3-bromopyridine was
subjected to the reported Suzuki cross-coupling reaction
conditions20 to provide the title compound. By our route, the
synthesis of PF-1247324 involving C−H fluorination was
completed with just three total isolations in 51% overall yield, a
major improvement in yield and step count over the published
synthesis. Furthermore, the route performed by medicinal
chemists required 120 h of total reaction time, while the route
we report here required less than 18 h.
Finally, we used our chemistry to prepare the non-nucleoside
reverse transcriptase inhibitor Intelence (etravirine, Scheme 4),
a compound used in the treatment of HIV. The route to this
compound developed by medicinal chemists occurred in five
steps and 9% yield from N-(4-cyanophenyl)guanidine hydro-
chloride.21 An alternative route used to prepare etravirine on
kilogram scale required four steps and occurred in 30% yield.22
Our synthesis of etravirine began with substitution of the 4-
chloro substituent in 2,4-dichloro-5-bromopyrimidine with 2,6-
dimethyl-4-cyanophenol, from which the solid product was
isolated after the addition of water. Next, substitution with 4-
aminobenzontirile and Boc protection in situ was conducted,
and the product was isolated in 88% yield. The installation of a
protecting group for the N−H bond was necessary for the
subsequent fluorination reaction to proceed. The synthesis of
etravirine was then completed by C−H fluorination of the
pyrimidine (71% yield by 19F NMR spectroscopy), substitution
with aqueous ammonia, and addition of HCl(aq) to cleave the
Boc group. Through this route, etravirine was prepared with
three total isolations in 45% overall yield in under 6 h of total
reaction time.
■ SUMMARY
In summary, we have developed a broadly applicable strategy
for the diverse, site-selective C−H functionalization of
pyridines and diazines. The reaction sequence occurs to
provide alkoxy-, aryloxy-, amino-, amido-, heteroaryl-, thio-,
and cyano-substituted heterocycles that can be difficult to
access through traditional methods. This tandem sequence is
attractive for the direct diversification of heteroarenes, due to
the exquisite site selectivity for C−H functionalization and the
mild conditions for the SNAr reaction. In addition, high site
selectivity for the fluorination of substrates containing more
than one heteroarene or more than one reactive C−H bond is
possible using this chemistry. Finally, the process of fluorination
and SNAr can allow medicinal compounds containing
substituted pyridines and diazines to be prepared by short
synthetic routes. We anticipate that these reactions will find
immediate use for both late-stage functionalization and efficient
syntheses of complex molecules.
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